Buradasınız

Anasayfa » Content

Sisplatin Nefrotoksisitesinde Nrf2/HO-1’nin Thymoquinone Tarafından Modülasyonu

Modulation of Nrf2/HO-1 by Thymoquinone During Cisplatin-Induced Nephrotoxicity

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2013
DOI: 
10.5262/tndt.2013.1002.09

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
OBJECTIVE: Side effects of cisplatin, such as nephrotoxicity, limit its use in chemotherapeutic regimens and indicate an agent that suppresses its toxicity. Thymoquinone (TQ), the predominant bioactive constituent present in black seed oil (Nigella sativa), has antiinfl ammatory, antioxidant and antitumor effects. We propose a protective mechanism of of TQ on cisplatin-nephrotoxicity in rats that is through modulation of Nrf2-mediated antioxidant induction and reduced inflammation. MATERIAL and METHODS: Twenty-eight male Wistar rats (8 weeks-old) were divided into four groups; Control (vehicle; 0.9% saline, 1 ml/kg body wt., p.o.), TQ (10 mg/kg body weight/day in drinking water for 5 days), cisplatin (a single injection of 7mg/kg body wt, i.p.) and TQ for 5 days in drinking water then a single injection of cisplatin. On day 10, all rats were sacrifi ced by cervical dislocation, kidneys were removed, and serum urea and creatinine were collected. RESULTS: Serum urea and creatinine levels were signifi cantly higher in cisplatin-treated rats compared with control rats. TQ-treatment signifi cantly decreased serum urea and creatinine levels. Cisplatin-treatment caused signifi cant downregulation of the nuclear NF-E2-related factor-2 (Nrf2), heme oxygenase-1(HO-1) and caused an increase in the levels of nuclear factor-kappa B (NF-κB). Interestingly, TQ supplementation signifi cantly improved the changes associated with cisplatin nephrotoxicity by increasing the levels of Nrf-2 and HO-1 and decreasing the levels of NF-κB. CONCLUSION: This study demonstrates the TQ targets NRF2/HO-1 and can be used as a potential agent against cisplatin-induced nephrotoxicity.
Bookmark/Search this post with
Abstract (Original Language): 
AMAÇ: Sisplatinin nefrotoksisite gibi sitotoksik etkileri, kemoterapi rejimlerinde kullanımını sınırlamakta ve toksik etkilerini baskılayacak bir ajana gereksinim doğmaktadır. Thymoquinone (TQ) çörek otu yağında bulunan biyoaktif bileşen olup, antiinfl amatuvar, antioksidan ve antitümör etkileri vardır. Bu çalışmada, ratlarda TQ’nin Nrf2 indüksiyonu ve antiinfl amatuvar etki yoluyla sisplatin nefrotoksisitesi üzerine olan koruyucu etkisini araştırdık. GEREÇ ve YÖNTEMLER: Bu çalışmada, TQ’in sisplatin aracılı nefrotoksisiteye etkisini ve bu süreçte in vivo olarak infl amasyonu baskılama mekanizmalarını araştırdık. Sekiz haftalık 28 erkek Wistar rat 4 gruba ayrıldı; kontrol (1 mg/kg oral %0,9’luk tuz çözeltisi), TQ (5 gün boyunca içme suyuna 10 mg/kg/gün), sisplatin (7 mg/kg, i.p. tek doz) ve içme suyuyla 5 günlük TQ uygulaması sonrası tek doz sisplatin enjeksiyonu yapılan grup. Onuncu günde tüm ratlardan servikal dislokasyon sonrası böbrek dokuları ile üre ve kreatinin ölçümü amaçlı serumları alındı. BULGULAR: Çalışmamız kontrol grubuna kıyasla sisplatin grubunda üre ve kreatinin değerlerinin anlamlı şekilde yüksek olduğunu göstermektedir (p<0,0001). TQ tedavisi serum üre ve kreatinin düzeylerini anlamlı şekilde azaltmıştır (p<0,001). Sisplatin tedavisi anlamlı biçimde (p<0,05) nükleer NF-E2 ilişkili faktör-2 (Nrf2) ve hem oksijenaz-1 (HO-1) downregülasyonuna neden olarak nükleer faktör-kappa B (NF-kB p65) düzeylerinde artmaya neden olmuştur. İlginç biçimde TQ desteği Nrf-2 ve HO-1 artışı ve NF-kB düzeylerinde anlamlı (p<0,05) azalmaya neden olarak sisplatin nefrotoksisitesine bağlı değişiklikleri düzeltmiştir. SONUÇ: Bu çalışma TQ’in NRF2/HO-1’i hedef aldığını ve sisplatin aracılı nefrotoksisiteye karşı potansiyel koruyucu bir ajan olarak kullanılabileceğini ortaya koymaktadır.
FULL TEXT (PDF): 
PDF icon ho-1nin-thymoquinone-tarafindan-modulasyonu.pdf
  • 2
182
187
  • Turkish

REFERENCES

References: 

1. Rabik CA, Dolan ME: Molecular mechanisms of resistance and
toxicity associated with platinating agents. Cancer Treat Rev 2007;
33: 9-23
2. Arany I, Safirstein RL: Cisplatin nephrotoxicity. Semin Nephrol
2003; 23: 460-464
3. Goldstein RS, Mayor GH: A minireview. The nephrotoxicity of
cisplatin. Life Sci 1983; 32: 685-690
4. Lee KW, Jeong JY, Lim BJ, Chang YK, Lee SJ, Na KR, Shin YT,
Choi DE: Sildenafi l attenuates renal injury in an experimental model
of rat cisplatin-induced nephrotoxicity. Toxicology 2009; 257: 137-
143
5. Yao X, Panichpisal K, Kurtzman N, Nugent K: Cisplatin
nephrotoxicity: A review. Am J Med Sci 2007; 334: 115-124
6. Pabla N, Dong Z: Cisplatin nephrotoxicity: Mechanisms and
renoprotective strategies. Kidney Int 2008; 73: 994-1007
7. Kotnis MS, Patel P, Menon SN, Sane RT: Renoprotective effect of
Hemidesmus indicus, a herbal drug used in gentamicin-induced
renal toxicity. Nephrology (Carlton) 2004; 9: 142-152
8. Rao NK, Nammi S: Antidiabetic and renoprotective effects of
the chloroform extract of Terminalia chebula Retz. seeds in
streptozotocin-induced diabetic rats. BMC Complement Altern
Med 2006; 7: 6-17
9. Shimeda Y, Hirotani Y, Akimoto Y, Shindou K, Ijiri Y, Nishihori T,
Tanaka K: Protective effects of capsaicin against cisplatin-induced
nephrotoxicity in rats. Biol Pharm Bull 2005; 28: 1635-1638
10. Sahin K, Tuzcu M, Gencoglu H, Dogukan A, Timurkan M, Sahin N,
Aslan A, Kucuk O: Epigallocatechin-3-gallate activates Nrf2/HO-1
signaling pathway in cisplatin-induced nephrotoxicity in rats. Life
Sci 2010; 87: 240-245
11. Sahin K, Tuzcu M, Sahin N, Ali S, Kucuk O: Nrf2/HO-1 signaling
pathway may be the prime target for chemoprevention of cisplatininduced
nephrotoxicity by lycopene. Food Chem Toxicol 2010; 48:
2670-2674
12. Sriram N, Kalayarasan S, Sudhandiran G: Epigallocatechin-3-
gallate augments antioxidant activities and inhibits infl ammation
during bleomycin-induced experimental pulmonary fi brosis through
Nrf2-Keap1 signaling. Pulm Pharmacol Ther 2009; 22: 221-236
13. Farombi EO, Shrotriya S, Na HK, Kim SH, Surh YJ: Curcumin
attenuates dimethylnitrosamine-induced liver injury in rats through
Nrf2-mediated induction of heme oxygenase-1. Food Chem Toxicol
2008; 46: 1279-1287
14. Kim J, Cha YN, Surh YJ: A protective role of nuclear factorerythroid
2-related factor-2 (Nrf2) in infl ammatory disorders. Mutat
Res 2010; 690: 12-2315. Gali-Muhtasib H, Roessner A, Schneider-Stock R: Thymoquinone:
A promising anti-cancer drug from natural sources. Int J Biochem
Cell Biol 2006; 38: 1249-1253
16. Arafa el-SA, Zhu Q, Shah ZI, Wani G, Barakat BM, Racoma I,
El-Mahdy MA, Wani AA: Thymoquinone up-regulates PTEN
expression and induces apoptosis in doxorubicin-resistant human
breast cancer cells. Mutat Res 2011; 706: 28-35
17. Swamy SM, Tan BK: Cytotoxic and immunopotentiating effects of
ethanolic extract of Nigella sativa L. seeds. J Ethnopharmacol 2000;
70: 1-7
18. Chakravarty N: Inhibition of histamine release from mast cells by
nigellone. Ann Allergy 1993; 70: 237-242
19. Abdel-Fattah AM, Matsumoto K, Watanabe H: Antinociceptive
effects of Nigella sativa oil and its major component, thymoquinone,
in mice. Eur J Pharmacol 2000; 400; 89-97
20. Badary OA, Nagi MN, al-Shabanah OA, al-Sawaf HA, al-Sohaibani
MO, al-Bekairi AM: Thymoquinone ameliorates the nephrotoxicity
induced by cisplatin in rodents and potentiates its antitumor activity.
Can J Physiol Pharmacol 1997; 75: 1356-1361
21. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye
S, Sarkar FH, Mohammad RM: Antitumor activity of gemcitabine
and oxaliplatin is augmented by thymoquinone in pancreatic cancer.
Cancer Res 2009; 69(13): 5575-5583
22. Jones MM, Basinger MA, Beaty JA, Holscher MA: The relative
nephrotoxicity of cisplatin, cis-[Pt(NH3)2(guanosine)2]2+, and
the hydrolysis product of cisplatin in the rat. Cancer Chemother
Pharmacol 1991; 29: 29-32
23. Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM: Protective
effects of the angiotensin II receptor blocker losartan on cisplatininduced
kidney injury. Chemotherapy 2009; 55: 399-406
24. Nagi MN, Mansour MA: Protective effect of thymoquinone against
doxorubicin-induced cardiotoxicity in rats: A possible mechanism
of protection. Pharmacol Res 2000; 41: 283-289
25. Awad AS, Kamel R, Sherief MA : Effect of thymoquinone on
hepatorenal dysfunction and alteration of CYP3A1 and spermidine/
spermine N-1-acetyl-transferase gene expression induced by
renal ischaemia-reperfusion in rats. J Pharm Pharmacol 2011; 63:
1037-1042
26. SAS User’s guide: Statistics. Cary, North Carolina, USA: SAS
institute, Inc., 2002
27. O’Dwyer PJ, Stevenson JP, Johnson SW: Clinical Status of
Cisplatin, Carboplatin and Other Platinum-Based Antitumor Drugs.
In: Lippert B, (ed). Cisplatin: Chemistry and Biochemistry of a
Leading Anticancer Drug. Zurich: Wiley-VCH, 1999: 29-70
28. Dogukan A, Tuzcu M, Agca CA, Gencoglu H, Sahin N, Onderci M,
Ozercan IH, Ilhan N, Kucuk O, Sahin K: A tomato lycopene complex
protects the kidney from cisplatin-induced injury via affecting
oxidative stress as well as Bax, Bcl-2, and HSPs expression. Nutr
Cancer 2011; 63: 427-434
29. Al-Majed AA, Abd-Allah AR, Al-Rikabi AC, Al-Shabanah OA,
Mostafa AM: Effect of oral administration of Arabic gum on
cisplatin-induced nephrotoxicity in rats. J Biochem Mol Toxicol
2003; 17: 146-15330. Sung MJ, Kim DH, Jung YJ, Kang KP, Lee AS, Lee S, Kim W,
Davaatseren M, Hwang JT, Kim HJ, Kim MS, Kwon DY, Park SK:
Genistein protects the kidney from cisplatin-induced injury. Kidney
Int 2008; 74: 1538-1547
31. Francescato HD, Costa RS, Júnior FB, Coimbra TM: Effect of
JNK inhibition on cisplatin-induced renal damage. Nephrol Dial
Transplant 2007; 22: 2138-2148
32. Francescato HD, Costa RS, Scavone C, Coimbra TM: Parthenolide
reduces cisplatin-induced renal damage. Toxicology 2007; 230:
64-75
33. Syed DN, Afaq F, Kweon MH, Hadi N, Bhatia N, Spiegelman
VS, Mukhtar H: Green tea polyphenol EGCG suppresses cigarette
smoke condensate-induced NF-kappaB activation in normal human
bronchial epithelial cells. Oncogene 2007; 26: 673-682
34. Prawan A, Kundu JK, Surh YJ: Molecular basis of heme oxygenase-1
induction: Implications for chemoprevention and chemoprotection.
Antioxid Redox Signal 2005; 7: 1688-170335. McNally SJ, Harrison EM, Ross JA, Garden OJ, Wigmore SJ:
Curcumin induces heme oxygenase 1 through generation of reactive
oxygen species, p38 activation and phosphatase inhibition. Int J
Mol Med 2007; 19: 165-172
36. Surh YJ, Kundu JK, Na HK: Nrf2 as a master redox switch in turning
on the cellular signaling involved in the induction of cytoprotective
genes by some chemopreventive phytochemicals. Planta Med 2008;
74: 1526-1539
37. Shoieb AM, Elgayyar M, Dudrick PS, Bell JL, Tithof PK: In vitro
inhibition of growth and induction of apoptosis in cancer cell lines
by thymoquinone. Int J Oncol 2003; 22: 107-113
38. Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H:
Thymoquinone and cisplatin as a therapeutic combination in lung
cancer: In vitro and in vivo. J Exp Clin Cancer Res 2010; 1: 29-87
39. Sethi G, Ahn KS, Aggarwal BB: Targeting nuclear factor-kappa
B activation pathway by thymoquinone: Role in suppression of
antiapoptotic gene products and enhancement of apoptosis. Mol
Cancer Res 2008; 6: 1059-1070

Thank you for copying data from http://www.arastirmax.com